Connect with us

China

McSally, Gaetz Push To Ensure US Taxpayer Funding Of Wuhan Lab Stops

Published

on

A joint letter written by Senator Martha McSally, R-AZ, and Congressman Matt Gaetz, R-FL, was sent to Congressional leaders Tuesday urging them to “ensure funding is cut off” to the Wuhan Virology Institute, which is currently being investigated for potentially being the source of the coronavirus.

“We were troubled by recent media reports that the National Institute of Health (NIH) has been funding secretive and dangerous laboratory research at the WIV for many years,” the two lawmakers wrote. “According to NIH’s website, the WIV is currently authorized by the NIH to receive taxpayer funding for animal research.”

Questions first began to surface after The Washington Post’s Josh Rogin wrote of State Department cables concerning the lab’s inadequate safety procedures and warning of a potential “SARS-like pandemic” stemming from bats, in January 2018, which U.S. Embassy officials in Beijing discovered two years before the coronavirus pandemic began. The lab is a biosafety level 4 facility, which means it conducts experiments on some of the world’s deadliest viruses such as Ebola.

Multiple sources later confirmed to Fox News that the virus likely came from the Wuhan lab and was used “as part of China’s attempt to demonstrate that its efforts to identify and combat viruses are equal to or greater than the capabilities of the United States.” Days later, U.S. officials confirmed to the news site that a “full-scale investigation” into whether the virus leaked from the lab was underway.

The recent letter from Capitol Hill echoes the concerns of the intelligence community. Moreover, McSally and Gaetz are encouraging Congressional action in an attempt to further divest U.S. taxpayer dollars from the Chinese government and their nefarious operations.

They wrote, “We’re sure you agree that taxpayers’ money should not be sent to a dangerous Chinese state-run bio-agent laboratory that lacks meaningful oversight from U.S. authorities and is run by adversaries with a history of lab leaks, including SARS, and deception about the causes and extent of deadly disease outbreaks, including COVID-19. Although President Trump has stated that his administration ‘will end that grant quickly,’ we hope to ensure that WIV will not receive federal funds in any future spending package.”

You may like

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.

China

China Says It’s Ready for Monkeypox and the West Isn’t

Published

on

China

As the Western press is becoming more and more concerned with monkeypox outbreaks, a recent bombshell report shows that Wuhan Institute of Virology (WIV) in China manipulated monkeypox to be more contagious in humans. This follows more evidence that the WIV had been experimenting with bat coronaviruses to increasingly infect humans.

But rather than agree to an honest investigation into the WIV and its role in spreading contagion around the world, China is once again trying to sell us an alternative reality. According to Chinese state-run media, it is China that is once again poised to be humanity’s savior and darling when it comes to fighting monkeypox, much like COVID-19. Not only that, but CCP press reporting shows evidence of China having an eerily well advanced infrastructure and gameplan to fight monkeypox. The West in contrast is not prepared, according to China.

Claim #1: China has the Wisdom to Fight Monkeypox

First, Chinese state-run media portray China as in a good position to combat monkeypox due to wisdom gleaned from combating COVID-19 and smallpox. One Global Times article noted that “[i]n the very early stage of the COVID-19 pandemic, China has taken the measures of ‘early identification, reporting, isolation, diagnosis and treatment.’ Under such guidance, China has become one of the most successful countries in the COVID fight.” Another Global Times article cites a World Health Organization official as stating that “China’s COVID-19 control measures in place and largely reduced international arrivals minimize the risks of contagion in China.” A third Global Times article, citing “experts,” claims that “China’s successful experience in eliminating smallpox would also help the country act if monkeypox enters China’s borders…”

Claim #2: Chinese Healthcare Infrastructure Is Well Prepared to Deal with Monkeypox

China is well ahead of the game in dealing with monkeypox, according to Chinese state-run media. Chinese experts “suggest preparation of testing and treatment capacities in advance” to proactively combat monkeypox, according to Global Times. And “drug research should start early so that China can still control [monkeypox] should it assume pandemic proportions,” according to China Daily.

China is apparently quite far along in this “preparation” and “research.”

There are “several” Chinese manufacturers that have already made monkeypox nucleic acid test kits, and that these “can be quickly put into mass production and on the domestic market once approved by the government,” according to a second Global Times article.  This article also states that Chinese manufacturer Liferiver Bio-Tech has a nucleic acid test that has already been ordered in China and abroad.

This same article also states that vaccine development faces “no technological problems” and a vaccine can be produced in China in a year if China’s drug administration administers “a rapid special review.” China’s CDC also has already stockpiled “millions” of doses of smallpox vaccine, produced “an emergency response technical plan on monkeypox, stocked monkeypox detection reagents, and conducted training on monkeypox nucleic acid PCR testing for provincial and municipal CDC professionals.”

Mirroring its earlier “mask diplomacy” for COVID-19, it looks like China is beginning to export its healthcare to the world to help combat monkeypox. China’s Sansure Biotech is ready to register its nucleic acid test kit for monkeypox abroad, according to Global Times. And Jiangsu Bioperfectus Technologies has already has its Monkeypox Virus Real Time PCR Kits in the international market, according to Global Times.

Claim #3: The West is Ill-Equipped to Handle Monkeypox

On the other hand, Chinese media portrays the West as ill-equipped to handle monkeypox. For example, according to one Global Times editorial, “[t]he COVID pandemic that killed more than 1 million people in the US has given a tragic lesson to the US and the West, but it still remains to be seen to what extent the US and the West learned from it.” The West’s “conspiracy theories” and “panic” contributed to the “Western countries’ poor response to COVID-19.” That CCP editorial also pontificates that “[i]t is hoped that Western countries hit by monkeypox can do a good job in responding to the outbreak. They should not misjudge the virus with outdated perceptions…”

Claim #4: Current Monkeypox spread originated from outside China

Chinese media avoids the possibility that this current monkeypox outbreak could have originated in China. One Global Times article claims that there have been no cases of monkeypox reported in China, and that China faces a threat from monkeypox due to the cases being “outside known epidemic areas of Africa.” The fact that many countries have now lifted bans against international travel is the culprit for increased risk of monkeypox transmission, according to anonymous source within the Chinese CDC as mentioned in that same article. Another Global Times article stated that China could quarantine inbound international travellers “if necessary.”

The CCP propaganda machine is at it again.  Much like it tries to portray itself as a leader in fighting COVID-19, China is beginning to run a similar propaganda campaign for monkeypox. China is using COVID-19, and increasingly now monkeypox, as vehicles to curry favor and deflect responsibility for spreading contagion around the world, and to grow markets for healthcare technology and supplies.

You may like

Continue Reading
Advertisement

Trending Now

Advertisement

Trending

Proudly Made In America | © 2022 M3 Media Management, LLC